来凯医药完成1850万美元A轮融资,奥博亚洲领投

原文始发于微信公众号(药时代):来凯医药完成1850万美元A轮融资,奥博亚洲领投

上海,6月4号, 2018/PRNewswire/ 来凯医药, 一家专注于创新药物研究与开发并拥有临床阶段产品的生物科技企业,今日宣布完成1850万美元的A轮融资,由奥博亚洲领投,安龙基金等跟投。

本轮融资将主要用于推进研究管线中的新药项目,并扩大产品线组合。来凯医药拥有三个处于临床I-II期阶段的抗肿瘤新药,主要针对中晚期肿瘤,包括前列腺癌卵巢癌乳腺癌胃癌等,目前正在欧美多个区域进行I-II期临床试验。来凯也已开始在中国申请临床试验许可,预期在年底可以全面启动。来凯也在开展早期的抗肿瘤和肝病新药研发,包括针对非酒精性脂肪性肝炎NASH)和肝纤维化等疾病领域。这些创新药产品具有自主知识产权,旨在用最尖端的医药科技满足患者需求。

“我们很荣幸得到世界一流的生物医疗领域专业投资基金奥博亚洲和中国科学院旗下风险投资基金安龙生命科学基金的认可。感谢投资人对来凯医药的理念、技术以及团队的肯定,” 来凯医药创始人和CEO吕向阳博士表示, “奥博亚洲和安龙基金的大力支持将有助于我们早期研发的不断深入,并且快速推进现有产品的临床开发,我们力争在不远的将来为患者和社会贡献更多的好药和新药”。

“吕向阳博士是一位具有丰富的新药研发经验的领导者,我们非常高兴有机会支持他带领下的团队为全世界的患者研发迫切需要的药物,”奥博亚洲创始合伙人和资深董事总经理王健博士说,“我们将充分借助奥博的全球平台、网络和资源来支持来凯医药的发展。”

关于来凯医药

来凯医药完成1850万美元A轮融资,奥博亚洲领投

来凯医药科技(上海)有限公司成立于2016年12月。公司位于上海张江高科技园区,是一家专注于新药研发的创新型企业。来凯医药在新一代小分子抗体靶向药物的研发上独树一帜。创始人暨CEO吕向阳博士和管理团队曾长期在国内外知名药企担任新药研发与管理职务,在疾病致病生物学机理和分子信号通路领域有深入的研究,并拥有多项国际发明专利,亲自参与和推动过多个新药的批准与上市。公司年轻而富有创造力的新药研发团队在加入来凯医药之前均在知名跨国药企接受过多年的新药发现和开发培训,在公司核心管理团队的带领下继续开发创突破性新药造福病患,建立国际领先的肝病和肿瘤的新药研发平台。

关于奥博亚洲

来凯医药完成1850万美元A轮融资,奥博亚洲领投

奥博资本创立于1989年,是全球最大的专注于生物医疗领域的投资公司,管理资产总额约130亿美元。奥博在全球范围内投资了约500家企业,涵盖生物制药医疗器械诊断、医疗服务等领域,投资阶段覆盖初创期、成长期、成熟期及上市后。奥博亚洲管理着三支专注于亚洲的风险投资和私募股权基金,总规模约11亿美元,投资了近50家优秀的医疗健康企业,包括再鼎医药(NASDAQ: ZLAB)、艾德生物 (SZ: 300685)、爱康医疗(HKEX: 01789)、ForteBio (被Pall Corporation收购) 、中美冠科 (TWSE: 6554)、时代天使、金唯智和亿腾等。

关于安龙基金

来凯医药完成1850万美元A轮融资,奥博亚洲领投

安龙基金是一只专注于国内早期生命科学与医疗健康领域的基金。基金管理合伙人赵春林博士有三十年业内经验,带领着一个拥有跨国企业,国内外研发,临床,成功创业以及投资经历的专业团队,基金基石投资人为中国科学院。安龙基金在中国科学院,清华大学,中国协和医科大学和百华协会等有广泛的经验及深厚的人脉,是生命科学及医疗健康领域创业者的强大资源和合作伙伴。安龙一期基金共投资了22家企业,包括与辉瑞制药合作的科辉创新新药研发孵化器及4家同创业者一起成立的公司,横跨生命科学,医药,医疗器械,及医疗服务领域。

联系人:

Amy Xie

来凯医药

Tel: +86 21 5071 6087

Email: pr@laeknatp.com

更多信息请访问:http://www.laeknatp.com

Shanghai,June 4,2018/PRNewswire/ Laekna Therapeutics, a clinical-stage biotechnology company, focused on the discovery and development of novel therapeutics, today announced the completion of a $18.5 million Series A round of financing, led by OrbiMed Asia. AnlongMed also participated in the financing.

The company plans to use the proceeds to advance the pipeline and expand the product portfolio. Laekna has three oral drug candidates at the clinical phase I-II stages for various oncology indications, including prostate, ovarian, breast and gastric cancers. Laekna has applied for IND applications to initiate clinical trials in China. It also has multiple drug discovery programs, targeting cancers and liver diseases, including NASH and hepatic cirrhosis.

“We are pleased to partner with OrbiMed, a leading global healthcare investment firm, and AnlongMed, a venture firm with roots in Chinese Academy of Sciences. The financial support from the top investment firms is a strong validation of Laekna’s capabilities in novel drug discovery and development,” says Dr. Chris Lu, founder and CEO of Laekna, “The investment will enable us to advance our pipeline rapidly and bring benefits to patients in the near future.”

“We are glad to partner with Chris Lu, a seasoned drug developer and excellent business leader, to create well-needed medicines for patients worldwide,”said Dr. Jonathan Wang, founding partner and Senior Managing Director of OrbiMed Asia.“We will leverage OrbiMed’s global platform, network and resources to support Laekna.”

About Laekna Therapeutics

Founded in December 2016, Laekna Therapeutics is a biotech company focused on innovative drug discovery and development. Targeting large unmet medical needs, Laekna is dedicated to developing new therapies for cancer and liver diseases. The company was founded by Dr. Chris Lu, the CEO, who has over two decades of experience in both small molecule and biologics drug discovery and development. Under his leadership, a team of experienced and energetic drug developers are tryingto bring breakthrough medicines to patients.

About OrbiMed Asia

Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm, with approximately $13 billion assets under management. It has successfully invested in approximately 500 private companies worldwide. OrbiMed invests in biopharmaceuticals, medical devices, diagnostics, and healthcare services at varying stages of maturity, from seed-stage venture capital to large publicly-traded companies. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling approximately $1.1 billion.It has made investments in nearly 50 companies, including Zai Lab(NASDAQ: ZLAB), AmoyDx (SZ: 300685), AK Medical (HKEX: 01789), ForteBio(acquired by Pall Corporation), CrownBio (TWSE: 6554), EA, Genewiz and Eddingpharm.

About AnlongMed

AnlongMed is a venture capital fund focuses on early stage life science and healthcare sectors. It is managed by a team led by Dr. Adam Zhao Chunlin, a veteran in life science with 30 years of experience, along with professionals with MNC, R&D, clinical, entrepreneurial and investment experience in both U.S. and China. The fund is anchored by Chinese Academy of Sciences. With extensive experience and connections from Chinese Academy of Sciences, Tsinghua University, Peking Union Medical College, and Bayhelix Group, AnlongMed strives to help entrepreneurs to start a venture in life science and healthcare in China. The fund has invested 22 firms from its first phase, including Netvation, a joint initiative toward new drug development between Chinese Academy of Science and Pfizer, Inc, 4 companies founded together with entrepreneurs across life science, biopharmaceutical, medical devices, and healthcare services.

Contact:

Amy Xie

Laekna Therapeutics

Tel: +86 21 5071 6087

Email: pr@laeknatp.com

For more information,please visit http://www.laeknatp.com

发布者:药时代,转载请首先联系contact@drugtimes.cn获得授权

发表评论

登录后才能评论
分享本页
返回顶部